DenovAI Biotech has secured $100,000 in investment capital, marking a significant step in its mission to advance therapeutic protein design. The company is focused on re-imagining the future of therapeutic protein design, believing that humanity is on the cusp of a protein design revolution poised to transform human health. DenovAI Biotech's vision is to revolutionize biologics discovery through its proprietary Generative AI and molecular biophysics platform, enabling the de-novo design of therapeutic proteins entirely from scratch.
The company specifically targets next-generation therapeutic antibodies and miniproteins. By leveraging its innovative platform, DenovAI Biotech aims to dramatically accelerate the pace of biologics discovery, reducing development timelines from years to weeks. Furthermore, its approach seeks to significantly lower the cost of preclinical development and mitigate the high failure rate commonly associated with drug development, by designing optimal molecules from the outset. DenovAI Biotech was established as a portfolio company of the AION Labs venture studio, benefiting from initial investment from leading pharmaceutical companies Pfizer, AstraZeneca, Merck, and Teva, alongside close support from Amazon Web Services (AWS) and additional financial backing from the Israel Innovation Authority, the Israel Biotech Fund, and Amiti Ventures.
This newly raised capital will be strategically deployed to further DenovAI Biotech's growth initiatives and expand its research and development capabilities. The funding underscores investor confidence in the company's innovative approach to drug discovery and its potential to create a substantial impact on the pharmaceutical landscape. DenovAI Biotech is poised to continue its work in pioneering advanced protein design, with a clear focus on bringing transformative new therapies to patients faster and more efficiently.
